CLRB - Cellectar Biosciences, Inc. Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

CLRB

CELLECTAR BIOSCIENCES, INC.

NASDAQ

$2.59

▲ UP 0.00% (0.00)

KEY STATISTICS

Market Cap$20.69 M

52w High$6.52

52w Low$2.20

Dividend Yield—

Frequency—

P/E-0.39

Volume25.66K

Shares Out.7.99M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

James V. Caruso

COMPENSATION 2026

Salary$676,000

Stock Awards$0

Incentive Plan Pay$169,000

All Other Comp.$0

Total$1,055,600

ABOUT

SECTOR

Healthcare

WENT PUBLIC

November 10, 2005

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

PRICE TARGET

Target High$11.00

Target Low$11.00

Target Median$11.00

Target Consensus$11.00

UPCOMING EARNINGS

DateNov 12, 2026

DayThursday

Rev. Est.$17.00M

NOV

THU

SPLIT RECORD

DATE	TYPE	RATIO
2025-06-24	Reverse	1:30
2025-06-23	Reverse	1:30
2022-07-22	Reverse	1:10
2022-07-21	Reverse	1:10
2018-07-17	Reverse	1:10
2018-07-16	Reverse	1:10
2016-03-07	Reverse	1:10
2016-03-06	Reverse	1:10
2014-06-20	Reverse	1:20
2014-06-16	Reverse	1:20

PRICE

$2.59 ▲ UP 0.00% (+$0.00)

OVERLAYS

About Cellectar Biosciences, Inc.

https://www.cellectar.com ↗

Cellectar Biosciences is a biopharmaceutical company developing cancer treatments, with lead drug CLR 131 in multiple Phase 2 trials for hematologic and pediatric cancers, and other PDC programs in preclinical or collaborations.

INDUSTRY

Biotechnology

A PRODUCT CELLECTAR BIOSCIENCES, INC. IS KNOWN FOR

Iopofosine I 131

Iopofosine I 131 is a targeted radiation therapy PDC for Waldenstrom's macroglobulinemia, FDA Breakthrough Therapy Designation, showing promise as a first-in-class treatment.